相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Accelerated and Blast Phase Myeloproliferative Neoplasms
Tania Jain et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis
Tania Jain et al.
BLOOD CANCER JOURNAL (2020)
Survival following allogeneic transplant in patients with myelofibrosis
Krisstina Gowin et al.
BLOOD ADVANCES (2020)
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry
Yadanar Lwin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
Tania Jain et al.
BONE MARROW TRANSPLANTATION (2019)
Cytomegalovirus Reactivation Promotes CD8+ T Cell Subset Recovery after Unmodified Allogeneic Hematopoietic Cell Transplantation
Tania Jain et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Donal P. McLornan et al.
HAEMATOLOGICA (2019)
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Marie Robin et al.
HAEMATOLOGICA (2019)
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolanos-Meade et al.
LANCET HAEMATOLOGY (2019)
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Donal McLornan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
Kavita Raj et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
Roni Tamari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen
Haris Ali et al.
BLOOD ADVANCES (2019)
Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation
Zinaida Peric et al.
BONE MARROW TRANSPLANTATION (2018)
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova et al.
BLOOD (2018)
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
F. M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Allogeneic Stem Cell Transplantation in Myelofibrosis
Tania Jain et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis
Alla Keyzner et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors
Stefania Bregante et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
Marie Robin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Mohamed Shanavas et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan et al.
BLOOD (2015)
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis
S. Slot et al.
BONE MARROW TRANSPLANTATION (2015)
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Yvette L. Kasamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
N. M. Kroeger et al.
LEUKEMIA (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
Vikas Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
Shivaprasad Manjappa et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Damiano Rondelli et al.
BLOOD (2014)
CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML
S. Ito et al.
BONE MARROW TRANSPLANTATION (2013)
Haploidentical Transplantation: Repurposing Cyclophosphamide
Richard J. Jones
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients
O. Ringden et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
A. Bacigalupo et al.
BONE MARROW TRANSPLANTATION (2010)
Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy
B. George et al.
TRANSPLANT INFECTIOUS DISEASE (2010)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation
Stefan O. Ciurea et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
Mary Eapen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
AH Filipovich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Allogeneic transplantation across major HLA barriers
PJ Henslee-Downey
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2001)
分享论文
